GlassScriptPhysician profile
Prodyot Ghosh
NPI 1780689257
$1,897.14
in general payments reported to CMS, 2019-2025
14 companies · $752 in 2025
The $752 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2021: $52.92 · 2022: $44.14 · 2023: $414 · 2024: $481 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.51 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.59 | 2023-2025 | |
| Janssen Biotech, INC. | $331.91 | 2024-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $309.32 | 2019-2023 | Captivator II, Exalt Model D |
| E.R. Squibb & Sons, L.L.C. | $189.55 | 2023-2024 | Zeposia |
| Perspectum Diagnostics LTD | $173.57 | 2024-2025 | Livermultiscan, Mrcp+ |
| Medtronic, INC. | $138.83 | 2024 | Gi Genius |
| Pfizer INC. | $106.99 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.88 | 2025 | Xifaxan |
| Madrigal Pharmaceuticals | $62.46 | 2025 | Rezdiffra |
| Lilly USA, LLC | $25.40 | 2024 | Omvoh |
| Ardelyx, INC. | $22.90 | 2025 | Ibsrela |
| Ucb, INC. | $19.89 | 2019 | |
| Shionogi INC | $18.09 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.76 | 2024 | Eohilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prodyot Ghosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.